PanCan's Precision Promise adaptive clinical trial programIMMray PanCan-d test is involved with PanCan's Early Detection Initiative.
https://pancan.org/research/early-detection-initiative/
https://pancan.org/news/new-early-detection-blood-tests-what-to-know/
[ As aside Illumina had attempted to acquire Grail for US$ 7.1 Billion but the merger has been overturned by the FTC with the FTC's issuance of a divestiture order. Pfizer faces the same challenge by the FTC with Pfizer's attempt to acquire Seagen for US$43 Billion ]
https://www.ftc.gov/news-events/news/press-releases/2023/04/ftc-orders-illumina-divest-cancer-detection-test-maker-grail-protect-competition-life-saving
Precision Promise is focused around providing an adaptive clinical trial program to accelerate new treatment options in pancreatic patients.
https://pancan.org/research/precision-promise/